Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study |
Jan 2024 |
Lancet Hematology |
Myelodysplastic Syndromes (MDS) |
Oral Iptacopan in Paroxysmal Nocturnal Hemoglobinuria |
Jun 2024 |
The New England Journal of Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Oral Iptacopan in Paroxysmal Nocturnal Hemoglobinuria |
Jun 2024 |
The New England Journal of Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Oral Iptacopan in Paroxysmal Nocturnal Hemoglobinuria. Reply |
Jun 2024 |
The New England Journal of Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria |
Mar 2024 |
The New England Journal of Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Oral therapy for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a revolution in progress |
Jul 2023 |
Expert Review of Anticancer Therapies |
Myelodysplastic Syndromes (MDS) |
Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents |
Dec 2020 |
Leukemia Research |
Myelodysplastic Syndromes (MDS) |
Outcomes of pediatric patients who relapse after first HCT for acute leukemia or MDS |
Mar 2021 |
Bone Marrow Transplantation |
Myelodysplastic Syndromes (MDS) |
Outpatient transfusions for myelodysplastic syndromes |
Dec 2020 |
Hematology. American Society of Hematology. Education Program |
Myelodysplastic Syndromes (MDS) |
Overview of the Management of Higher-Risk Myelodysplastic Syndromes |
May 2023 |
The Cancer Journal |
Myelodysplastic Syndromes (MDS) |